Founded in 2014, Kono Chem Co., Ltd is an export-oriented production enterprise supported by the State Department of Commerce.
Kono Chem covers an area of 312,000 square meters, with scientific and technological personnel accounting for more than 35%. The headquarter of the company is located in Xi'an, Shaanxi Province. It consists of two chemical fermentation workshops, a pilot-scale reaction workshop and a provincial R&D center. Since the establishment of the company, it has been recognized by customers at home and abroad and audited by authoritative laboratories in accordance with ISO9000, ISO14001 and specifications. At present, the company's main products involve biopharmaceuticals, flavors and fragrances, pesticide intermediates, veterinary drug development, and some custom synthesis.

With comprehensive EHS management and high-quality advantages, Kono Chem sells 85% of its products in more than 50 countries around the world, and has established long-term strategic partnerships with multinational companies such as CIPLA, BIOCON, and DSM. The company adheres to the business tenet of "integrity and diligence", with an efficient research and development system, simple and diligent employees, and a responsible corporate culture, and sincerely invites domestic and foreign colleagues who are willing to cooperate for a long time to join the mission for the development of the chemical raw material industry.

Doxorubicin is a non-cycle-specific anti-tumor drug with a broad anti-tumor spectrum and can be clinically used for breast cancer, lung cancer, lymphoma, ovarian cancer and other cancers. As a second-line antitumor drug, doxorubicin can be used for treatment when the drug resistance is the first choice.

Doxorubicin hydrochloride interacts with DNA by intercalating and inhibiting macromolecular biosynthesis, inhibiting topoisomerase II of DNA supercoiling. Doxorubicin prevents the closing of the DNA double helix, thereby disrupting the replication of the DNA strand. By intercalation, doxorubicin can also act on transcriptionally active chromatin, resulting in changes in histones. The results show that the DNA damage response, epigenome and transcriptome are uncontrolled in doxorubicin-treated cells.

It is used for the treatment of acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's disease and non-Hodgkin's disease lymphoma, breast, lung, ovarian cancer